Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ANI Pharmaceuticals Inc gives H2 2014 outlook in line with analysts' estimates


Monday, 4 Aug 2014 08:30am EDT 

ANI Pharmaceuticals Inc:Expects H2 2014 net revenues to be between $28 -$30 mln.Expects H2 2014 adjusted non-GAAP earnings per share, excluding non-cash stock compensation expense, to be between $0.90 and $1.00 per share.Expects H2 2014 adjusted non-GAAP EBITDA, excluding non-cash stock compensation expense, to be between $14 -$15 mln.H2 2014 revenue of $29 mln, EPS of $0.93, EBITDA of $14 mln - Thomson Reuters I/B/E/S. 

Company Quote

68.12
0.58 +0.86%
4:00pm EDT